Publications by authors named "S V S Goutam"
Bradyarrhythmias, characterized by heart rates of <60 bpm due to conduction issues, carry risks of sudden cardiac death and falls. Pacemaker implantation is a standard treatment, but the interplay between bradyarrhythmias, coronary artery disease (CAD), and patient attributes requires further exploration. This study was a retrospective hospital record-based study that analyzed data from 699 patients who underwent pacemaker implantation for symptomatic bradyarrhythmias between February 2019 and February 2022.
View Article and Find Full Text PDFRadiotherapy (RT) is often utilized for symptom control at the end of life. Palliative RT (pRT) may not be taken to completion by patients, thus decreasing clinical benefits and adversely impacting resource allocation. We determined rates of incomplete pRT and examined predictors of non-completion using an electronic questionnaire.
View Article and Find Full Text PDFAlthough immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, patients with pre-existing autoimmune diseases (PADs) have largely been excluded from clinical trials evaluating this drug class. This study evaluates the effectiveness and safety of ICI therapy in individuals with PAD in a real-world setting. A retrospective study of patients exposed to ICI therapy between 2012 and 2019 was conducted.
View Article and Find Full Text PDFArticle Synopsis
- A study analyzed the impact of age on survival rates in patients with advanced melanoma who received immunotherapy, focusing on two age groups: under 65 and 65 years or older.
- Out of 497 patients studied, younger patients (younger than 65) had a longer median overall survival (22.2 months) compared to older patients (17.1 months), particularly in cutaneous melanoma cases.
- The use of a combination treatment (nivolumab plus ipilimumab) significantly improved survival outcomes compared to single-agent PD-1 therapy, reflecting the importance of treatment choice in managing melanoma.
Importance: Treatment-free survival (TFS) represents an alternative time-to-event end point, accurately characterizing time spent free of systemic therapy, providing a more patient-centric view of immune checkpoint inhibitor (ICI) therapy regimens. There remains a lack of studies evaluating TFS outcomes among patients with advanced melanoma who are receiving immunotherapy, especially outside of the clinical trial setting.
Objective: To evaluate TFS outcomes for patients with advanced melanoma receiving first-line ICI therapy outside of a clinical trial setting.